BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, May 21, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

March 4, 2021

View Archived Issues
Doctor reviews Corvista findings with patient

Corvista advancing heart disease tech with $65M series C

Corvista Health Inc. has raised $65 million in a series C equity financing led by Ambix Life Science Fund I LP. The new funds are earmarked for ongoing research, product development and commercialization of the company’s noninvasive, point-of-care (POC) solution for rapid detection of heart disease. Joining Ambix in the round were Medventure Partners and several new and existing investors. With this latest infusion, Corvista has raised a total of nearly $100 million. Read More
Device overlayed on transparent head illustration

Neurolief's neuromodulation headset wins FDA clearance for migraine

Neurolief Ltd. received FDA clearance for its Relivion system for home treatment of acute migraine. The noninvasive multichannel brain neuromodulation system, worn as a headset, stimulates the occipital and trigeminal nerves. Read More
Liver tumor treatment conceptual illustration

Histosonics tests sonic beam therapy for liver tumors

Histosonics Inc. is testing its investigational histotripsy technology to destroy liver tumors in two clinical trials in the U.S. and Europe, with the goal of seeking regulatory clearance for the platform in 2022. The technology uses the science of histotripsy, a form of therapeutic focused ultrasound, to mechanically destroy targeted primary and metastatic liver tumors from outside the body. Read More
digital-health-telehealth-phone-doctor.png

Telehealth takeaway: Don’t forget about the patient

A bad patient experience with telehealth can blunt adoption regardless of the incentives for developers and doctors. Griffin Mulcahey, chief compliance officer at Wheel Health Inc., of Austin, Texas, said during a recent webinar that users of these digital health apps and telemedicine programs may need assistance to get up to speed on an application, a critical effort that may make the difference between success and failure in telehealth. Read More
Psychology-disorders-heads

Researchers ID new method to monitor schizophrenia drug in blood

HONG KONG – Researchers at Ben-Gurion University of the Negev (BGU) in Israel have developed a way to instantly monitor blood levels of the antipsychotic drug clozapine. BGU’s solution is based on an electrochemical microsensor developed by Hadar Ben-Yoav from BGU’s Department of Biomedical Engineering and Ilse Katz Institute for Nanoscale Science and Technology. Read More

Appointments and advancements for March 4, 2021

New hires and promotions in the med-tech industry, including: Bioventus, Cureatr, Diaceutics, Egenesis, Neurescue. Read More

Financings for March 4, 2021

Med-tech firms raising money in public or private financings, including: Cutera, Mednow, Owens & Minor. Read More

In the clinic for March 4, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Agendia, Farapulse, Ocon Medical, Preceptis Medical. Read More

Other news to note for March 4, 2021

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abiomed, Accessdx, Biointellisense, C2i Genomics, Cloudbreak Health, Genetic Technologies, Infinity Biologix, Medquest Pharmacy, Qna Dx, Gravity, Kits, Medicortex, Philips, Qiagen, Relay Medical, Revolugen, Sonde, Swift, Zepp. Read More

Regulatory actions for March 4, 2021

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Controlrad, Misonix. Read More

Regulatory front for March 4, 2021

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: AHRQ: Patient portals underused in ED visits; Butterfly IQ scores well on cost, but supporting data limited. Read More

BioWorld MedTech’s Diagnostics Extra for March 4, 2021

Keeping you up to date on recent developments in diagnostics, including: Rapid POC test for respiratory infections may reduce antibiotic use; Risk-stratification tools help conserve ventilator, ICU bed use; Diverse populations, long reads give genome insights; Neurons contribute to their own lack of regeneration. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 20, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 19, 2026
  • Microscopic view of the ebola virus

    WHO declares Ebola outbreak a public health emergency of international concern

    BioWorld
    The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
  • Acid alpha-glucosidase molecular structure isolated on black

    ‘Detargeted’ targeted gene therapy improves activity in Pompe

    BioWorld
    A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
  • Nxera Pharma prepares and tests new GPR17 antagonists

    BioWorld Science
    Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing